156 filings
Page 2 of 8
8-K
w6avq7sp4p1xqu
9 May 23
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
4:11pm
8-K
2k1rt11k
28 Apr 23
Regulation FD Disclosure
6:00am
8-K
5zgn swcr
21 Apr 23
Entry into a Material Definitive Agreement
5:21pm
8-K
3pokl5
11 Apr 23
Regulation FD Disclosure
9:00am
8-K
qmpb4nid2la6l
28 Mar 23
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
4:10pm
8-K
jmyt 7dc8e7
17 Mar 23
Termination of a Material Definitive Agreement
4:15pm
EFFECT
ae045m nm6q
3 Jan 23
Notice of effectiveness
12:15am
CORRESP
zjor 1wu0cmod8d
30 Dec 22
Correspondence with SEC
12:00am
UPLOAD
0qlewfd3
29 Dec 22
Letter from SEC
12:00am
8-K
q4xd pyeg
13 Dec 22
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
4:14pm
8-K
4wtii8kvc94mc5ms2mjp
13 Dec 22
Regulation FD Disclosure
8:33am
8-K
oi9p9mx sovjksydconk
9 Nov 22
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
4:06pm
8-K
4vy 39hhj1kmk1d
4 Nov 22
Entry into a Material Definitive Agreement
5:00pm
8-K
3x7jiv6k xg0qn5ops
1 Nov 22
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
6:36pm
8-K
qeb9jfufdg5 sw
1 Sep 22
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of
5:09pm